Monitoring Treatment Response in Women With Breast Cancer Utilizing FLT-PET/CT
18 Years
N/A
Female
Adult Women With a New Diagnosis of Invasive Breast Cancer (Have Not Undergone Treatment)
Trial Information
Monitoring Treatment Response in Women With Breast Cancer Utilizing FLT-PET/CT
Our overall goal is to use this clinical trial as a platform to validate fibroblast
activation protein (FAP) as a biomarker for the tumor microenvironment and to explore the
dynamic interaction between proliferating tumor cells and the tumor microenvironment. Our
long term goal is to develop new drugs that will target the tumor microenvironment as novel
therapeutic and chemoprevention strategies.
Inclusion Criteria:
- Breast biopsy positive for an invasive malignancy (core needle, mammatone, or
incisional biopsy)
- Participants must be planning to have surgery at the Hospital of the University of
Pennsylvania
- Participants must be able to tolerating lying on the table for about an hour
- Newly diagnosed primary breast cancer, which is classified as being operable (T1-T4)
Exclusion Criteria:
- Pregnant women
- History of severe renal disease
- Prior history of breast cancer of the study breast within the last five years.
Type of Study:
Interventional
Study Design:
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Outcome Measure:
Sensitivity and specificity of FLT-PET comparing with standard FDG-PET
Safety Issue:
No
Authority:
United States: Food and Drug Administration
Study ID:
UPCC 01109
NCT ID:
NCT01018251
Start Date:
March 2009
Completion Date:
October 2012
Related Keywords:
- Adult Women With a New Diagnosis of Invasive Breast Cancer (Have Not Undergone Treatment)
- Breast Neoplasms
Name | Location |
|---|---|
| Abramson Cancer Center of the University of Pennsylvania | Philadelphia, Pennsylvania 19104-4283 |
